The ABHD10 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional studies of the mitochondrial deacylase ABHD10. This product consists of a heterogeneous pool of Huh-7 cells carrying diverse ABHD10 gene disruptions, providing a loss-of-function model without clonal selection. The polyclonal format preserves biological variability and is suitable for population-level assays while minimizing clone-specific artifacts.
The parental Huh-7 cell line is a well-differentiated human hepatocellular carcinoma line originally derived from a male Japanese patient in 1982. Huh-7 cells are widely employed in liver cancer research, hepatitis C virus replication studies, and drug metabolism investigations due to their hepatic characteristics and ease of culture. This host provides a relevant hepatocellular context for examining mitochondrial and metabolic pathways in liver cancer.
ABHD10 functions as a mitochondrial acyl-protein deacylase that removes fatty acyl modifications from proteins, thereby contributing to mitochondrial proteostasis and morphology. Its expression is regulated by transcription factors including PGC-1??, NRF1, and p53. ABHD10 acts on downstream targets such as fatty acylated mitochondrial proteins and subunits of the electron transport chain. Knockout of ABHD10 is predicted to cause hyperacylation of these substrates, potentially impairing their function and disrupting mitochondrial quality control. The ABHD10 pathway intersects with signaling networks involving SIRT5, p53, MYC, ??-catenin, and AKT, all of which are frequently deregulated in hepatocellular carcinoma.
In the Huh-7 hepatocellular carcinoma background, loss of ABHD10 provides a unique tool to dissect the role of mitochondrial deacylation in liver cancer biology. Because Huh-7 cells retain many hepatocyte functions and are permissive for HCV replication, this knockout model allows integrated studies of how mitochondrial dysfunction??specifically impaired protein acylation turnover??influences cancer hallmarks such as metabolic reprogramming, apoptosis resistance, and invasive behavior. Moreover, it permits examination of crosstalk between mitochondrial homeostasis and oncogenic drivers like MYC and ??-catenin in a liver-specific context.
Typical applications include investigation of mitochondrial deacylation in liver cancer using Western blotting for acylated proteins and mitochondrial functional assays (ATP production, membrane potential). The model supports drug metabolism studies in hepatocarcinoma cells, screening of agents targeting mitochondrial pathways, and analysis of mitochondrial morphology by immunofluorescence. Researchers can correlate ABHD10 loss with changes in metabolic gene expression via RT-qPCR and assess effects on cell viability, apoptosis, migration, and invasion. For further information or to discuss custom gene editing services, please contact Ascent Research.
